Company logo

MGNX - MacroGenics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Rockville, United States

MGNX price evolution
MGNX
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Current assets
Cash $47.33 $123.47 $190.53 $188.97
Short term investments $136.66 $120.15 $108.37 $108.35
Net receivables $14.9 $10.39 $13.76 $45.25
Inventory $4.6 $4.39 $3.98 $6.48
Total current assets $218.2 $279.56 $334.7 $367
Long term investments
Property, plant & equipment $36.03 $37.68 $38.68 $39.4
Goodwill & intangible assets
Total noncurrent assets $53.24 $55.69 $57.46 $58.91
Total investments $136.66 $120.15 $108.37 $108.35
Total assets $271.44 $335.25 $392.16 $425.91
Current liabilities
Accounts payable $3.73 $15.5 $6.17 $9.82
Deferred revenue $31.93 $20.65 $25.89 $30.04
Short long term debt $4.84 $4.68 $4.52 $4.37
Total current liabilities $67.1 $74.58 $68.86 $69.92
Long term debt $19.51 $20.79 $22.02 $23.21
Total noncurrent liabilities $26.13 $21.05 $31.86 $36.94
Total debt $24.35 $25.47 $26.55 $27.57
Total liabilities $93.23 $95.63 $100.72 $106.87
Shareholders' equity
Retained earnings -$1040.38 -$973.94 -$915.91 -$863.03
Other shareholder equity -$0.28 -$0.06 -$0 $0
Total shareholder equity $178.21 $239.62 $291.44 $319.05
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $123.47 $181.13 $126.47 $220.13
Short term investments $120.15 $91.4 $89.28 $12.73
Net receivables $10.39 $23.08 $12.74 $29.58
Inventory $4.39
Total current assets $279.56 $312.59 $239.78 $269.12
Long term investments
Property, plant & equipment $37.68 $42.23 $48.21 $56.71
Goodwill & intangible assets
Total noncurrent assets $55.69 $66.15 $72.72 $63.01
Total investments $120.15 $91.4 $89.28 $12.73
Total assets $335.25 $378.74 $312.5 $332.13
Current liabilities
Accounts payable $15.5 $8.03 $4.31 $4
Deferred revenue $20.65 $11.38 $19.85 $40.72
Short long term debt $4.68 $3.99 $3.02
Total current liabilities $74.58 $50.67 $45.17 $59.94
Long term debt $20.79 $25.26 $27.55
Total noncurrent liabilities $21.05 $32.19 $36.71 $29.31
Total debt $25.47 $29.25 $30.57
Total liabilities $95.63 $82.86 $81.87 $89.25
Shareholders' equity
Retained earnings -$973.94 -$771.82 -$642.08 -$490.27
Other shareholder equity -$0.06 -$0.01 $0.02 -$0
Total shareholder equity $239.62 $295.88 $230.63 $242.88
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Revenue
Total revenue $11.1 $14.15 $15.66 $30.76
Cost of revenue $0.05 $0.95 $1.67 $0.02
Gross Profit $11.05 $13.2 $14 $30.73
Operating activities
Research & development $61.44 $55.85 $49.82 $55.78
Selling, general & administrative $16.25 $15.58 $17.16 $15.23
Total operating expenses $77.69 $71.44 $66.98 $71.01
Operating income -$66.64 -$58.24 -$52.99 -$40.28
Income from continuing operations
EBIT -$66.44 -$58.02 -$52.89 -$39.94
Income tax expense
Interest expense
Net income
Net income -$66.44 -$58.02 -$52.89 -$39.94
Income (for common shares) -$66.44 -$58.02 -$52.89 -$39.94
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $77.45 $104.88 $64.19 $60.12
Cost of revenue $2.65
Gross Profit $74.8 $104.88 $64.19 $60.12
Operating activities
Research & development $214.58 $193.2 $195.31 $190.83
Selling, general & administrative $63.01 $42.74 $46.06 $40.5
Total operating expenses $277.59 $235.94 $241.37 $231.33
Operating income -$202.79 -$131.06 -$177.19 -$171.21
Income from continuing operations
EBIT -$202.12 -$129.74 -$151.81 -$171.45
Income tax expense
Interest expense
Net income
Net income -$202.12 -$129.74 -$151.81 -$171.45
Income (for common shares) -$202.12 -$129.74 -$151.81 -$171.45
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Net income -$66.44 -$58.02 -$52.89 -$39.94
Operating activities
Depreciation $2.91 $2.95 $2.8 $2.78
Business acquisitions & disposals
Stock-based compensation $5.27 $5.41 $6.36 $6.07
Total cash flows from operations -$57.7 -$54.31 -$14.79 -$45.69
Investing activities
Capital expenditures -$1.42 -$1.38 -$2.13 -$2.07
Investments -$17.07 -$12.18 -$0.48 $15.88
Total cash flows from investing -$18.48 -$13.55 -$2.62 $13.82
Financing activities
Dividends paid
Sale and purchase of stock $0.04 -$0.76 $20.43 $2.45
Net borrowings
Total cash flows from financing $0.04 $0.8 $18.97 $2.35
Effect of exchange rate
Change in cash and equivalents -$76.14 -$67.06 $1.56 -$29.53
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$202.12 -$129.74 -$151.81 -$171.45
Operating activities
Depreciation $11.26 $11.96 $10.85 $8.28
Business acquisitions & disposals
Stock-based compensation $23.13 $20.68 $19.57 $16.52
Total cash flows from operations -$143.83 -$111.9 -$134.27 -$153.23
Investing activities
Capital expenditures -$6.2 -$5.91 -$4.29 -$24.95
Investments -$30.41 -$1.88 -$75.07 $81.6
Total cash flows from investing -$36.61 -$7.79 -$79.36 $56.64
Financing activities
Dividends paid
Sale and purchase of stock $122.78 $174.34 $119.97 $104.99
Net borrowings
Total cash flows from financing $122.78 $174.34 $119.97 $104.99
Effect of exchange rate
Change in cash and equivalents -$57.66 $54.66 -$93.66 $8.4
Fundamentals
Market cap $187.07M
Enterprise value $164.09M
Shares outstanding 61.33M
Revenue $71.67M
EBITDA -$205.84M
EBIT -$217.29M
Net Income -$217.29M
Revenue Q/Q -34.24%
Revenue Y/Y -33.69%
P/E ratio -0.86
EV/Sales 2.29
EV/EBITDA -0.80
EV/EBIT -0.76
P/S ratio 2.61
P/B ratio 1.05
Book/Share 2.91
Cash/Share 0.77
EPS -$3.54
ROA -61.00%
ROE -84.52%
Debt/Equity 0.40
Net debt/EBITDA -0.22
Current ratio 3.25
Quick ratio 3.18